File photo: The laboratory of HymonBio Co in Taicang, Jiangsu province. [Photo/WeChat account: tcsrmtzx]

Taicang-based HymonBio Co and Neo Nostics Co can produce COVID-19 test kits for 1 million and 200,000 people respectively every day, local media reported on March 14.

"Our daily production capacity has exceeded 1 million and can expand at any time to meet epidemic prevention needs," said Professor Hua Tsen, chief technology officer of HymonBio Co.

Two HymonBio products have been authorized by the FDA microbiological and equipment department in the United States and the King's College Hospital NHS Foundation in the United Kingdom.

HymonBio Co was established in Taicang Port in 2015. Its co-founders were from the University of Texas and Chinese Academy of Sciences.

The products of Neo Nostics Co. [Photo/WeChat account: tcsrmtzx]

Neo Nostics Co also started operations in Taicang in 2015 and has since been focusing on the R&D and exports of In Vitro Diagnostics (tests done on samples such as blood or tissue that have been taken from the human body).

The company's products are exported to countries and regions including Germany, Russia, and Hong Kong.

China recently approved COVID-19 antigen testing as a supplementary means to improve early detection. Ten domestically made antigen kits have already received approval for home use.

The COVID-19 antigen test is a supplementary diagnostic method to nucleic acid testing and will help improve early detection, according to a notice published on the National Health Commission's website.